Here is another possibility. Unlikely IMO but who

Here is another possibility. Unlikely IMO but who the hell knows.

From YMB.

“Take a step back and ask yourself why they would put Tanya Urbich as chair who served as “General Counsel for Paulson Investment Company, LLC, a registered broker-dealer that provides investment banking services” and Antonio Migliarese, CFO, as acting president who has experience with “M&A Transactions”. Confucius says that when you put two finance people in charge of a pharma company, they are clearly looking to be acquired Add to that Sidley which is a “preeminent global M&A practice that is engaged in the full spectrum of public and private mergers and acquisitions and private equity transactions across a variety of industries.”

Now when you are looking to be acquired, you don’t say you are looking to be acquired. You say you are initiating a “Search for New CEO With Requisite Pharmaceutical Industry Experience”. You also get rid of the CEO that was most against selling the company.

This is not one or more partners. IMHO, Cytodyn will be acquired….and it won’t be at .50c a share. Gilead has most to lose if Cytodyn is acquired by someone else, significant risk from a lot of their patents now expired, and, therefore, most to gain from acquiring this platform drug with a long lifeline. The “New CEO” will be the CEO of a major pharma…possibly Gilead.

My .50 cents worth of thought”